Filing Flows › Monte Rosa Therapeutics (GLUE) › How it makes money
How Monte Rosa Therapeutics (GLUE) makes money
Monte Rosa Therapeutics (GLUE) made $54.4M of revenue in the third quarter 2026 (Q3 2026), +326% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $54.4M | 100.0% |
| Income tax | $716K | 1.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9.0M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +38% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | 80× |
From Monte Rosa Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Monte Rosa Therapeutics make money?
Monte Rosa Therapeutics (GLUE) made $54.4M of revenue in the third quarter 2026 (Q3 2026), +326% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.